This from Today’s Financial News:

Maryland-based Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) has high hopes for its drug VEC-162. This treatment mimics the action of melatonin — the hormone that that regulates the body’s internal clock.

Vanda is testing the effectiveness of VEC-162 to treat sleep disorders.

Over 60 million adults in the U.S. alone suffering from some form of insomnia. Yet only about 15% seek treatment. Some fear side effects like grogginess and dry mouth.

Others are afraid of becoming reliant on a sleep aid. In fact, many such treatments, including Lunesta and Ambien, are categorized as Schedule IV controlled substances. This indicates that abuse of these drug could lead to physical or psychological dependence.

So far, all indications are that VEC-162 has no significant side effects.

How’s your circadian rythym?

In clinical trials, participants were asked to initiate sleep five hours prior to their usual bedtines.

Those who took the drug experienced improvements in overall sleep efficiency, and a greater ability to both initiate and to maintain sleep as compared to participant given a placebo.

The drug, in effect, resets the body’s circadian clock that governs the sleep-wake cycle.

Circadian rythym sleep disorders are experienced by shift workers and suffers of jet-lag and this drug could hold the key to relief.

Insiders are buying and so should you!

I recommend you buy shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) at or under 75 cents and hold on for double-digit gains.

Source: Rest Easy With Vanda Pharmaceuticals Inc. (VNDA)